This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Ashton thumbnail

a 10-year-old who loves planes. He draws them all the time. In fact, he wants to design them when he grows up. Ashton was born with Noonan syndrome and is currently treated with Norditropin®.

 

Dosing: Recommended 0.066 mg/kg/day1

 

Efficacy: 77% of children have reached a height within the normal range after about 4 years2

William thumbnail

a 4-year-old from Frankfurt, Germany. He was born with GHD and wants to be a pilot when he grows up. William is treated with Norditropin®.

 

Dosing: 0.025-0.035 mg/kg/day1

 

Efficacy: Average growth rate shown is 11.4 cm / year3
Gigi thumbnail

seen here with her twin sister. These two love sweets and plan on opening up their own candy shop when they grow up. Gigi was born with SGA, while her sister wasn’t. Gigi is being treated with Norditropin®.

 

Dosing: 0.035 mg/kg/day1

 

Efficacy: 98% of children reached a height within the target range, and 85% reached a normal adult height4
Logan thumbnail

a 6-year-old girl who wants to be a fashion designer when she grows up. Logan was born with Turner Syndrome. She is treated with Norditropin®.

 

Dosing: 0.045-0.067 mg/kg/day1

 

Efficacy: 83% of the girls reached a height within the range of normality5
Will thumbnail

who was born with a growth disorder. Will wants to help other kids that have similar conditions and is planning on going to medical school; he wants to specialise in paediatrics. Will is currently being treated with Norditropin®.

 

Dosing: Restart treatment at 0.2-0.5 mg/day (can be tailored based on individual’s serum IGF-1)1

 

Efficacy: Increased BMC (Bone Mineral Content), cortical bone thickness, lean body mass, and decreased fat mass6–9

The information contained in this site is intended for healthcare professionals only. This site is not intended to provide medical advice and/or treatment guidance. This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice.

 

SmPC

The Summary of Product Characteristics (SmPC) is based on the EU SmPC of May 2021. Registration conditions differs from country to country. Always refer to the full local SmPC before prescribing Norditropin®. Norditropin is registered in EU, USA, Canada, Latin America Middle East and Asia.

1.

RCP Norditropin®.

2.

Lee et al. Noonan syndrome and Turner syndrome patient respond similarly to 4 years’ growth-hormone-naive therapy: longitudinal analysis of growth-hormonenaive patients enrolled in the Nordinet® international outcome study and the ANSWER program. Int J Pediatr Endocronol. 2015; 2015(1):17.

3.

Savendahl et al. Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial. J Clin Endocrinol Metab. 2020 Apr;105(4):1-5.

4.

Van Pareren et al. Adult Height after Long-Term, Continuous Growth Hormone (GH) Treatment in Short Children Born Small for Gestational Age: Results of a Randomized, Double-Blind, Dose-Response GH Trial. J Clin Endocrinol Metab.2003 Aug;88(8):3584-90.

5.

Van Pareren et al. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab. 2003 Mar;88(3):1119-25.

6.

Hyldstrup et al. Growth hormone effects on cortical bone dimensions in young adults with childhood-onset growth hormone deficiency. Osteoporos Int. 2012 Aug;23(8):2219-26.

7.

Shalet S et al. Effect of growth hormone (GH) treatment on bone in postpubertal gh-deficient patients: a 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab. 2003 Sep;88(9):4124-9.

8.

Vahl N et al. Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebocontrolled study. J Clin Encocrinol Metab. 2000 May;85(5):1874-81.

9.

Attanasio AF et al. Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. J Clin Endocrinol Metab. 2004 Oct;89(10):4857-62.

10.

Horikawa et al. Long-term efficacy and safety of two doses of Norditropin (somatropin) in Noonan syndrome: a 4-year randomized, double-blind, multicenter trial in Japanese patients. Endocr J. 2020 Aug 28;67(8):803-818. doi: 10.1507/endocrj.EJ19-0371